BMS and Calithera Announce Clinical Collaboration to Evaluate nivolumab in combination with CB-839 for Renal Cell Carcinoma

bristol-calithera

December 21, 2016

Bristol-Myers Squibb Company and Calithera Biosciences, Inc., a clinical stage biotechnology company focused on discovering and developing new small molecule drugs directed against tumor metabolism and tumor immunology targets for treating cancer, have announced a clinical trial collaboration to evaluate the Opdivo of Bristol-Myers Squibb in combination with  CB-839 of Calithera in patients with clear cell renal cell carcinoma (ccRCC). CB-839 is an orally administered glutaminase inhibitor currently in Phase 1/2 clinical studies.

Fouad Namouni, M.D., senior vice president, head of Oncology Development, Bristol-Myers Squibb, said: “Influencing the tumor microenvironment remains a key area of focus of research, and we are excited to explore the potential benefits of Opdivo plus CB-839 in an effort to advance new combination therapies for difficult to treat cancers.”

“The combination with Opdivo follows our strategy to combine CB-839 with therapies to improve outcomes for RCC patients. We believe that by blocking glutamine consumption in tumors, and redirecting this key nutrient for cell growth and proliferation to T-cells, CB-839 could enhance the effects of Opdivo. With support from Bristol-Myers Squibb, Calithera is excited to advance this combination into the Phase 2 portion of CX-839-004, our ongoing study in ccRCC patients,” said Susan Molineaux, CEO of Calithera Biosciences.

BMS and Calithera Announce Clinical Collaboration to Evaluate nivolumab in combination with CB-839 for Renal Cell Carcinoma last edit: 2017-01-05T16:23:09+00:00 da Luca

Leave a Reply

*The views and opinions expressed on IgeaHub belong to the authors only. They do not represent the views or opinions of any company or organization.

Follow Us

Join us

All rights reserved. Terms of use and Privacy Policy

Design by PT Webmaster

%d bloggers like this:
Skip to toolbar